drugset / Trial / NCT01683396

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

NCT01683396

Phase 2 Completed 87 enrolled XOMA (US) LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of active inflammatory, erosive osteoarthritis of the hand.

Timeline

Start
2012-07
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject gevokizumab Monoclonal antibody Subcutaneous

Indications